Exploring Cancer Cells’ Adaptation to Treatment with CRISPR Epigenome Editing: A Review

Background: State changes in cancer cells adapting to treatment
A review published in Cancer Letters examines CRISPR-based epigenome editing as a tool for studying cancer cell state transitions and treatment resistance. The central approach is to regulate chromatin states at specific genomic loci without changing the DNA sequence, allowing researchers to investigate cancer cell adaptation. This paper reviews relevant molecular mechanisms, research applications, and limitations; it is not an experimental study demonstrating a new anticancer effect.
Cancer cells do not exist in a single fixed state. In breast cancer, glioblastoma, and other cancers, cells may reversibly shift among proliferative, stem-like, invasive, and drug-tolerant states in response to intracellular regulatory programs and signals from the tumor microenvironment. Such cellular plasticity contributes to intratumoral heterogeneity, immune evasion, treatment resistance, and disease progression.
These processes involve interacting signaling pathways and transcriptional networks, chromatin remodeling, DNA methylation, histone modifications, and non-coding RNAs. The review describes how this epigenetic instability contributes to state transitions that arise stochastically or are induced by treatment. Understanding the relationship between chromatin changes and cell states requires approaches that investigate causality, beyond observing phenomena that occur together.
Key findings: Tools for investigating causal links between chromatin and cell function
The main approach examined in the review combines catalytically inactive Cas9 (dCas9) with effector domains responsible for epigenetic regulation. The abstract lists DNMT3A, TET1, KRAB, and p300 as examples. These tools are used to investigate how chromatin modifications at specific genomic loci affect cell function without altering the DNA sequence itself.
The targets of this regulation are gene expression programs involved in cell state transitions, cell lineage determination, and adaptive resistance. This approach provides an experimental framework for examining how cell properties change when chromatin states are regulated and for modeling how tumors adapt to environmental changes. The review covers applications in research on tumor heterogeneity, adaptation to the microenvironment, immune evasion, and treatment resistance.
However, the provided abstract does not report sample sizes, control groups, editing efficiency, or the magnitude of anticancer effects in individual experiments. Based on this material alone, it is difficult to determine how much drug sensitivity is restored by regulating a particular gene or which editing tool performs better. The reversibility of cancer cell state transitions should not be taken to mean that editing effects are always reversible.
Implications and outlook: Conditions for advancing toward treatment development
The research value of epigenome editing lies in going beyond observing epigenetic changes in cancer cells to investigating their function through targeted regulation. Researchers can examine the link between chromatin regulation and changes in cell state and build evidence for subsequent studies of therapeutic targets. The review’s outlook is similarly limited to the prospect that experimental frameworks for analyzing cancer cell plasticity can inform future treatment development.
Barriers to therapeutic application remain. The abstract identifies delivery of editing tools, persistence of epigenetic modifications, differences in responses across biological contexts, and limitations in translating findings into therapies as challenges. Potential use as a research tool alone does not establish that it can produce reliable treatment effects in patients. Claims that resistance prevention or prediction of patient-specific drug administration timing has been achieved would also exceed the scope of this abstract.
The scope and limitations of the paper can be checked in the bibliographic record and abstract available in Europe PMC.
Cellular plasticity is a fundamental driver of tumor heterogeneity, cancer stemness, immune evasion, therapeutic resistance, and disease progression. In malignancies such as breast cancer and glioblastoma, tumor cells undergo reversible phenotypic transitions between proliferative, stem-like, invasive, and drug-tolerant states in response to intrinsic regulatory programs and extrinsic signals from the tumor microenvironment. These adaptive dynamics are governed by complex interactions among signaling pathways, transcriptional networks, chromatin remodeling, DNA methylation, histone modifications, non-coding RNAs, and immune-mediated microenvironmental cues. Such epigenetic instability enables stochastic and therapy-induced shifts between alternative cellular states, thereby contributing to tumor evolution, metastasis, resistance to targeted therapies, and variable responses to immunotherapy. Understanding the mechanisms that govern epigenetic plasticity remains a central challenge in cancer biology. Recent advances in CRISPR/dCas9-based epigenome editing have provided powerful experimental tools for investigating the functional consequences of locus-specific chromatin modifications without altering the underlying DNA sequence. Catalytically inactive Cas9 (dCas9) fused to epigenetic effector domains, including DNMT3A, TET1, KRAB, and p300, enables targeted modulation of gene expression programs implicated in cell-state transitions, lineage specification, and adaptive resistance. These technologies offer a versatile platform for interrogating causal relationships between chromatin states and cellular phenotypes and for modeling mechanisms of tumor adaptation. This review examines the molecular basis of epigenetic plasticity in cancer, evaluates current CRISPR-based epigenome editing strategies, and discusses their application in studying tumor heterogeneity, microenvironment-driven adaptation, immune escape, and therapy resistance. This study highlights emerging oppor
In cancer research, determining whether chromatin changes that appear after treatment directly contribute to resistance requires linking observations to functional validation. Epigenome editing is an experimental tool for addressing this question. For example, researchers who select a candidate genomic locus associated with resistance can investigate whether epigenetic regulation at that site changes the cell state or drug response. This scenario illustrates a research application discussed in the review; it is not a result demonstrating the efficacy of a particular target. Advancing toward treatment development requires validating delivery feasibility, persistence of effects, and differences in responses across biological conditions. The provided abstract alone is insufficient to determine treatment effects in patients or the timing of clinical application.